Cell therapy for advanced digestive cancers
Part of Cancer, Digestive system clinical trials.
This trial tests a new cell therapy called BGT007 for people with advanced cancers of the digestive system (esophagus, stomach, pancreas, or colon) that have not responded to standard treatments. The therapy uses your own immune cells, modified to target a protein on your cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old and willing to sign a consent form.
- You have esophageal, stomach, pancreatic, or colorectal cancer that has come back or spread, and has not responded to at least two standard treatments.
- A tumor tissue test shows a specific protein target (target protein positive).
- Your blood counts, liver, and kidney function are within certain ranges (your doctor will confirm).
- You are not pregnant, have no active infections, and are not on long-term steroids or blood thinners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called BGT007H for people with advanced digestive tract cancers (esophagus, stomach, pancreas, or colon) that have not responded to or stopped working after at least two prior treatments. The goal is to see if this therapy can help shrink tumors or slow the disease.
This trial tests a new type of cell therapy (BGT007H cells) for people with advanced gastrointestinal cancers that have not responded to at least two standard treatments. The therapy uses your own immune cells that are modified to target and attack the cancer.
This trial is testing a new cell therapy called BGT007 for people with advanced pancreatic or colorectal cancer that has not responded to other treatments. The goal is to see if this treatment can shrink tumors or slow the cancer's growth.
This trial tests a new cell therapy (BGT007H) for people with advanced pancreatic cancer that has not responded to earlier treatments. The goal is to see if it is safe and can help shrink or control the cancer.
This trial tests a new treatment using your own immune cells that are trained to attack cancer. It is for people with advanced stomach, colon, or esophageal cancer who have already tried other treatments that didn't work.
This trial tests a new type of immune cell therapy called CBG131 CAR-T cells for people with advanced stomach or pancreatic cancer that has stopped responding to standard treatments. The therapy targets a protein called CLDN18.2 on cancer cells, and the study aims to see if it can shrink tumors.
Hear when a new Gastrointestinal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.